> Details

Pusch, Fabian Fadi; García, Heathcliff Dorado; Xu, Robin; Guergen, Dennis; Bei, Yi; Brueckner, Lotte; Roeefzaad, Claudia; von Stebut, Jennifer; Bardinet, Victor; Gonzalez, María del Rocío Chamorro; Eggert, Angelika; Schulte, Johannes H.; Hundsdoerfer, Patrick; Seifert, Georg; Haase, Kerstin; Schaefer, Beat; Wachtel, Marco; Kühl, Anja A.; Ortiz, Michael; Wengner, Antje M.; Scheer, Monika; Henssen, Anton G.

Abstract 1667: Elimusertib shows stronger antitumor activity than standard of care chemotherapy in pediatric solid tumor models

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Abstract 1667: Elimusertib shows stronger antitumor activity than standard of care chemotherapy in pediatric solid tumor models
  • Contributor: Pusch, Fabian Fadi; García, Heathcliff Dorado; Xu, Robin; Guergen, Dennis; Bei, Yi; Brueckner, Lotte; Roeefzaad, Claudia; von Stebut, Jennifer; Bardinet, Victor; Gonzalez, María del Rocío Chamorro; Eggert, Angelika; Schulte, Johannes H.; Hundsdoerfer, Patrick; Seifert, Georg; Haase, Kerstin; Schaefer, Beat; Wachtel, Marco; Kühl, Anja A.; Ortiz, Michael; Wengner, Antje M.; Scheer, Monika; Henssen, Anton G.
  • imprint: American Association for Cancer Research (AACR), 2023
  • Published in: Cancer Research
  • Language: English
  • DOI: 10.1158/1538-7445.am2023-1667
  • ISSN: 1538-7445
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title> <jats:p>Elimusertib is a small molecule inhibitor of ataxia telangiectasia and Rad3-related protein (ATR) currently being tested in clinical trials. Despite the known anti-tumor activity in various cancer entities, its effect on many pediatric malignancies remains unknown. We assessed the preclinical activity of elimusertib in a cohort of over 40 cell lines and 30 patient-derived xenograft (PDX) models derived from pediatric solid tumors. Elimusertib reduced tumor growth in all PDX models, with 50% of them achieving stable disease, partial or total response, even in those derived from relapsed tumors. Moreover, elimusertib outperformed the effect of standard of care chemotherapy, particularly in alveolar rhabdomysarcoma. Molecular characterization of the models provide information on response biomarkers with diagnostic potential. In summary, elimusertib shows strong preclinical anti-tumor activity in pediatric solid tumor models, that may translate to clinically meaningful responses in patients.</jats:p> <jats:p>Citation Format: Fabian Fadi Pusch, Heathcliff Dorado García, Robin Xu, Dennis Guergen, Yi Bei, Lotte Brueckner, Claudia Roeefzaad, Jennifer von Stebut, Victor Bardinet, María del Rocío Chamorro Gonzalez, Angelika Eggert, Johannes H. Schulte, Patrick Hundsdoerfer, Georg Seifert, Kerstin Haase, Beat Schaefer, Marco Wachtel, Anja A. Kühl, Michael Ortiz, Antje M. Wengner, Monika Scheer, Anton G. Henssen. Elimusertib shows stronger antitumor activity than standard of care chemotherapy in pediatric solid tumor models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1667.</jats:p>
  • Access State: Open Access